Peritoneal catheter exit-site infections: Predisposing factors, prevention and treatment

International Journal of Artificial Organs

Volumn 26, Issue 8, 2003, Pages 698-714

  Thodis, E ^a   Passadakis, P ^a   Ossareh, S ^b   Panagoutsos, S ^a   Vargemezis, V ^a   Oreopoulos, Dim G ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Exit site infection; PD catheters; Prevention; Treatment

Indexed keywords

DIALYSIS; FLAVONOIDS; METABOLITES; TECHNOLOGY TRANSFER;

ACHILLES' HEEL; EXIT SITE INFECTION; LOWER FREQUENCIES; PD CATHETER; PERITONEAL DIALYSIS; PREDISPOSING FACTORS; PREVENTION; S. AUREUS; TREATMENT; WORLD-WIDE BASIS;

CATHETERS;

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BACITRACIN; CEFAZOLIN; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CHLORHEXIDINE; CIPROFLOXACIN; FUSIDATE SODIUM; GENTAMICIN; IMIDAZOLE; OFLOXACIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; SULCONAZOLE; VANCOMYCIN; WARFARIN;

ACHILLEA; ANTIBIOTIC PROPHYLAXIS; BACTERIUM CARRIER; CATHETER; CATHETER INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE PREDISPOSITION; DOUBLE LUMEN TUBE; DRUG ANTAGONISM; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HUMAN; INCIDENCE; LIVER DISEASE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONITIS; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0141955937     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880302600802     Document Type: Review

References (148)

1. Churchill DN, Taylor DW, Vas SI, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): A multicenter randomized clinical trial comparing type Y connector disinfectant system to standard system. Perit Dial Int 1989; 9: 159-63.
2. Lindblad AS, Hamilton RW, Novak JW. Complications of peritoneal catheters. In: Lindblad AS, Novak JW, Nolph KD, eds. Continuous Ambulatory Peritoneal Dialysis in the USA Final Report of the National CAPD Registry. Dordrecht: Kluwer, 1989, pp. 157-166.
3. Lupo A, Tarchini R, Cancarini G, Catizone L, Cocchi R, De Vecchi A, et al.. Long-term outcome in CAPD: A 10 year survey by the Italian Cooperative Peritoneal Dialysis Study Group. Am J Kidney Dis 1994; 24: 826-37.
4. Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int 1998; 18: 11-33.
5. Copley JB. Prevention of peritoneal dialysis catheter-related infections. Am J Kidney Dis 1987; 10: 401-7.
6. Akyol AM, Porteous C, Brown MW. A comparison of two types of catheters of CAPD. Perit Dial Int 1990; 210: 63-6.
7. Nielson PK, Hemmingsen C, Friis SU, Ladefoged J, Olgaard K. Comparison of straight and curled Tenckhoff peritoneal dialysis catheters implanted by the subcutaneous technique: A prospective randomized study. Perit Dial Int 1995; 15: 18-21.
8. US Renal Data System 1992. Annual data report VI. Annual data report VI. Catheter related factors and peritonitis risk in CAPD patients. Am J Kidney Dis 1992; 20 (suppl 2): S48-54.
9. Warady BA, Sullivan EK, Alexander SR. Lessons from the peritoneal dialysis patient database: A report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int 1996; 49 (suppl 53): S68-71,.
10. Honda M, Litaka K, Kawaguchi H, Hoshi S, Akashi S, Kohsaa T, et al. The Japanese National Registry Data in Pediatric CAPD Patients: A report of the study group of pediatric conference. Perit Dial Int 1996; 16: 269-275
11. Favazza A, Petri R, Montanaro D, Boscutti G, Bresakola F, Mioni G. Insertion of a straight peritoneal catheter is an arcuate subcutaneous tunnel by a tunneler: Long-term experience. Perit Dial Int 1995; 15: 357-62.
12. Mitwalli A, Kim D, Wu G, et al. Single-vs, double-cuff peritoneal catheters: A prospective controlled trial. In: Khanna R, Nolph K, Prowant B, Twardowski A, Oreopoulos D, eds. Advances in CAPD: Proceedings of the Fifth Annual CAPD Conference. Kansas City. Mo, February 1985, Toronto: University of Toronto Press 1985: 35-40.
13. Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am J Kidney Dis 2000; 36: 1014-9.
14. Swartz R, Messana J, Starmann B, Weber M, Reynolds J. Preventing S. aureus infection during chronic peritoneal dialysis. J Am Soc Nephrol 1991; 2: 1085-91.
15. Liberec T, Chmielewski M, Lichodziejewska-Niemierko M, Renke M, Zadrozny D, Rutkowski B. Survival and function of Tenckhoff peritoneal catheters after surgical or percutaneous placement: One center experience. Letter. Int J Artif Organs 2003; 26: 174-5.
16. Tenckhoff J, Schechter H. A bacteriologically safe peritoneal access device. Trans Am Soc Artif Intern Organs 1968; 14: 181-7.
17. So SKK, Mahan JD, Jr, Mauer SM, Sutherland DER, Nevins TE. Hickman catheter for pediatric hemodialysis: A 3-year experience. Trans Am Soc Artif Intern Organs 1984; 30: 619-23.
18. Raaf JH. Results from use of 826 vascular access devices in cancer patients. Cancer 1985; 55: 1312-21.
19. Golper TA, Brier ME, Bunke M. Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 38: 428-36.
20. Twadowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP. The need for a "Swan-Neck" permanently bent, arcuate peritoneal dialysis catheter. Perit Dial Bull 1985; 5: 219-23.
21. Lye WC, Kour N-W, Van Der Straaten J, et al. A prospective randomized comparison of the Swan-Neck, coiled and straight Tenckhoff catheters in patients on CAPD. Perit Dial Int 1996; 16(suppl 1): S333-5.
22. Eklund BH, Honkanen EO, Kalan AR, Kyllonen LE. Catheter configuration and outcome in CAPD: A prospective comparison of two catheters. Perit Dial Int 1994; 14: 70-4.
23. Hwang TL, Huang CC. Comparison of Swan-Neck catheter with Tenckhoff catheter for CAPD. In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications 1994; 10: 203-5.
24. Monceif JW, Popovich RP. Moncrief-Popovich catheter: Implantation technique and clinical results. Perit Dial Int 1994; 14 (suppl): S56-8.
25. Danielsson A, Blohme L, Traneaus A, Hylander B. A prospective randomized study on the effect of a subcutaneously "buried" peritoneal dialysis catheter technique versus standard technique on the incidence of peritonitis and exit-site infection. Perit Dial Int 2002: 22; 214-9.
26. Prischl FC, Wallner M, Kalchmair H, et al. Initial subcutaneous embedding of the peritoneal dialysis catheter - A critical appraisal of this new implantation technique. Nephrol Dial Transplant 1997; 12: 1661-7.
27. Moncrief JW, Popovich RP. Presentation at the XVIII Annual CAPD Conference, Nashville, TN, February 24, 1998.
28. Twardowski ZJ, Nichols WK, Nolph KD, et al. Swan-Neck presternal peritoneal dialysis catheter. Perit Dial Int 1993; 13 (suppl): S130-2.
29. Kubota R, Kanazawa M, Takahashi Y, To H, Ishiguro N, Tomino Y. Implantation of peritoneal catheter using Moncrief technique: Aiming for fewer catheter-related complications. Perit Dial Int 2001; 21 (suppl 3): S205-8.
30. Twardowski ZJ, Prowant BF, Nichols WK, Nolph KD, Khanna R. Six year experience with Swan-Neck presternal peritoneal dialysis catheter. Perit Dial Int 1998; 18: 598-602.
31. Prowant BF, Warady BA, Nolph KD. Peritoneal dialysis catheter exit site care: Results of an international survey. Perit Dial Int 1993; 13: 149.
32. Prowant BF, Schmidt LM, Twardowski ZJ, et al. Peritoneal dialysis catheter exit site care. Am Nephrol Nurs Assoc J 1988; 15: 219.
33. Fuchs J, Gallagher ME, Jackson Bey D, et al. A prospective randomized study of peritoneal catheter exit site care. Dial Transplant 1990; 19: 81.
34. Keogh AM. Complications of peritoneal dialysis: Peritonitis and exit site infections: Per Dial Int 1996; 16 (suppl 1): S464-7.
35. Fair PA. Hygiene for health. Nurs Times 1994; 90: 71-2.
36. Piraino B, Bernardini J, Sorkin M. The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections and catheter loss in patients on CAPD. Am J Kidney Dis 1986; 8: 436-40.
37. Herfrich GB, Pechan BW, Aligani MR, Barnard WF, Rakowski TA, Winchester JF. Reduction of catheter complications with lateral placement. PD Bulletin 1983; 3 (suppl): S2-4.
38. Robinson RJ, Leapman SB, Wetherington M, Hamburger RJ, Fineberg NS, Filo RS. Surgical considerations of peritoneal dialysis. Surgery 1984; 96: 723-9.
39. Keane WF, Everett ED, Golper TA, et al. Peritoneal dialysis-related peritonitis treatment recommendations 1993 update. Perit Dial Int 993; 13: 14-28.
40. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M. New strategies to prevent S. aureus infections in peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 669-76.
41. Wikdahl AM, Engman U, Stemayr BG, Sorensen JG. One-dose cefuroxime IV and IP reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant 1997; 12:157-60
42. Bennett-Jones DN, Martin J, Barratt AJ, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. Adv Perit Dial 1988; 4: 147-50.
43. Lye WC, Lee EJC, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scand J Urol Nephrol 1992; 26: 177-80.
44. Moss B, Squire JR, Topley E. Nose and skin carriage of Staphylococcus aureus in patients penicillin. Lancet 1948; 254: 320-5.
45. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 1982; 248: 1493-5.
46. Zimmerman SW, O'Brien M, Wiedenhoeft FA, Johnson CA. Staphylococcus aureus peritoneal catheter-related infections: A cause of catheter loss and peritonitis. Perit Dial Int 1988; 8: 191-4.
47. Sesso R, Draibe S, Castelo A, Sato I, Leme I, Barbosa D, Ramos O. Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1989; 31: 264-8.
48. Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 1995; 41: 127-31.
49. Fernandez C, Gaspar C, Torrellas A, Vindel A, Saez-Nieto JA, Cruzet F, Aguilar L. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium oitment for eliminating nasal carriage of Staphylococcus aureus hospital personnel. J Antimicrob Chemother 1995; 35: 399-408.
50. Parras F, Guerrero MC, Bouza E, Blazwuez MJ, Moreno S, Menarwuez MC, Cercenado E. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-9.
51. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related enfections. Perit Dial Int 1994; 14: 137-144.
52. Blowey DL, Warady BA, McFarland KS. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv Perit Dial 1994; 10: 297-9.
53. Burkart JM. Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Perit Dial Int 1996; 16 (suppl 1): S340-6.
54. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of Staphylococcal infections: A review of recent experience. J Hosp Infect 1994; 27: 81-98.
55. Hanevold CD, Fisher MC, Waltz R, Bartosh S, Baluarte HJ. Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Pediatr Nephrol 1995; 9: 609-11.
56. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients: Its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258-62.
57. Herwaldt LA. S. aureus nasal carriage: Role in continuous ambulatory peritoneal dialysis-associated infections. Perit Dial Int 1993; 13 (suppl 2): S301-5.
58. Holley J, Bernardini J, Piraino B. Catheter infections in insulin-dependent diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1991; 11: 347-50.
59. Bargman JM. Nasal carriage of S. aureus in dialysis patients. Semin Dial 1995; 8: 220-5.
60. Weinstein HJ. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med 1959; 260: 1303-130.
61. White A. Increased infection rates in heavy nasal carriers of coagulase - Positive staphylococci. Antimicrob Agents Chemother 1963; 3: 667-70.
62. Moss B, Squire JR, Topley E, Johnston CM. Nose and skin carriage of S. aureus in patients receiving penicillin. Lancet 1948: 320-35.
63. Tulloch LG. Nasal carriage in staphylococcal skin infections. Br Med J 1954: 912-3.
64. Pignatari A, Pfaller M, Hollis R, Sesso R, Leme I, Herwaldt L. S. aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 1990; 28: 1898-902.
65. Holley JL, Bernardini J, Piraino B. Risk factors for tunnel infections in continuous peritoneal dialysis. Am J Kidney Dis 1991; 18: 344-8.
66. Zimmerman SW, O'Brien M, Wiedenhoeft FA, Johnson CA. S. aureus peritoneal catheter - Related infections: A cause of catheter loss and peritonitis. Perit Dial Int 1988; 8: 191-4.
67. Zimmerman SW, Johnson CA, O'Brien M. Long-term survivors on peritoneal dialysis. Am J Kidney Dis 1987; 10: 241-9.
68. Abraham G, Savin E, Ayiomamitis A, et al. Natural history of exit-site infection in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1988; 8: 211-6.
69. Piraino B, Bermardini J, Sorkin M. The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1986; 8: 436-40.
70. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ. Straphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. J Am Med Assoc 1982; 248: 1493-5.
71. Wanten GJA, Van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by S. aureus in patients on continuous ambulatory peritoneal dialysis: A prospective study. Perit Dial Int 1996; 16: 352-6.
72. Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, Pignatari A, Draibe S, Ajzen H. Effect of sodium fusidate and ofloxacin on S. aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1994; 41: 370-6.
73. Polepou MF, Johnson AP, Cookson BD, Beatti H, Charlett A, Woodford N. Evaluation of disc diffusion and E test for determining the susceptibility of Staphylococcus aureus to mupirocin. J Antimicrob Chemother 1998; 42: 577-83.
74. Waite NM, Webster N, Laurel M, Johnson M, Fong IW. The efficacy of exit-site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. Am J Kidney Dis 1997; 29: 763-8.
75. Zimakoff J, Bangsgaard-Pedersen F, Bergen L, Baago-Nielsen J, Daldorph B, Espersen F, Gahrn-Hansen B, Hoibi N, Jepsen OB, Joffe P, Kolmos HJ, Klausen M, Kristoffersen K, Ladefoged J, Olesen-Larsen S, Rosdahl VT, Scheibel J, Storm B, Tofte Jensen P. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark. The Danish Study Group of Peritonitis in Dialysis (DASPID). J Hosp Infect 1996; 33: 289-300.
76. Piraino B. A review of Staphylococcus aureus exit-site and tunnel infection in peritoneal dialysis patients. Am J Kidney Dis 1990; 16: 89-95.
77. Beard-Pegler MA, Gabelish CL, Stubbs E, Harbour C, Robson J, Falk M, Benn R, Vickery A. Prevalence of peritonitis-associated coagulase-negative staphylococci on the skin of continuous ambulatory peritoneal dialysis patients. Epidemiol Infect 1989; 102: 365-78.
78. Kingwatanakul P, Warady BA. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. Adv Perit Dial 1997; 13: 281-4.
79. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, Moncalian J. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long-term results. Am J Kidney Dis 1993; 22: 708-12.
80. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Legget J,O; Brein M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18: 225-31.
81. Pignatari A, Jones RN, Barrett MR, Sesso R, Leme I, Pfaller MA. Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD associated S. aureus infection. J Chemother 1991; 3: 108-16.
82. Bryan CS, Wilson RS, Meade P, Sill LS. Topical antibiotic ointment for staphylococcal nasal carriers: Survey of current practices and comparison of bacitracin and vancomycin ointments. Infect Control 1980; 1: 153-6.
83. Favero MS, Tokars JI, Arduino MJ, Alter MJ. Nosocomial infections associated with hemodialysis. In: Mayhall CG, ed. Hospital Epidemiology and Infection. Philadelphia, PA: Lippincott Williams & Wilkins, 1999, pp. 897-917.
84. Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro C, Deitchmann SD. Guideline for infection control in healthcare personnel. 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998; 19: 407-63.
85. Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32: 425-44.
86. Parenti MA, Hatfield SM, Leyden JJ. Mupiricin: A topical antibiotic with a unique structure and mechanism of action. Clin Pharm 1987; 6: 761-70.
87. Hughes J, Mellows G. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J 1978; 176: 305-18.
88. Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985; 27: 495-8.
89. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: A review of recent experience. J Hosp Infect 1994; 27: 81-98.
90. Casewell MW, Hill RLR. Elimination of nasal carriage of S. aureus with mupirocin (pseudomonic acid) - A controlled trial. J Antimicrob Chemother 1986; 17: 365-72.
91. Doebbeling B, Breneman D, March R, Reagan D, Wenzel R. Multi-centre study of elimination of S. aureus nasal carriage with calcium mupirocin ointment in healthy subjects. In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Oct 11-14, Anaheim, Abstract no. 1688.
92. Doebbeling BN, Pfaller MA, Reagan DR, Houston AK, Hollis RJ, Wenzel RP. Investigation of the epidemiology of S. aureus carriage. In: Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991; Abstract no. 27: 103.
93. Redhead RJ, Lamp YJ, Rowsell RB. The efficacy of calcium mupirocin in the eradication of nasal S. aureus carriage. Br J Clin Pharmacol 1991; 45: 252-4.
94. Cederna JE, Terpenning MS, Ensberg M, Bradley SF, Kauffman CA. S. aureus nasal colonization in a nursing home: Eradication with mupirocin. Infect Control Hosp Epidemiol 1990; 11: 13-6.
95. Jimenez ML, Del Rey MC, Henar Carrasco N, Alarcon T, Lopez-Brea M. Effect of nasal mupirocin in an outbreak of methicillin-resistant S. aureus. In: Proceedings of the 17th International Congress of Chemotherapy; 1991; Berlin. Abstract no. 998.
96. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemia in hemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-9.
97. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophyl axis. N Engl J Med 1986; 315: 91-6.
98. Coles GA The effect of intranasal mupirocin on CAPD exit site infections (Abstract). J Am Soc Nephrol 1994; 5: 439.
99. Bernardini J, Lutes R, Johnston JR, Holley JL, Piraino B. Randomized trial of rifampin versus mupirocin to prevent S. aureus infections in PD patients (Abstract). Perit Dial Int 1995; 15 (suppl): S517.
100. Faller B. New findings on the prevention of exit-site infections. European multicenter trial results. 15th Annual Conference on Peritoneal Dialysis. Baltimore, MD, 1995: 147-64.
101. Berardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of S. aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27: 695-700.
102. Thodis E, Bhaskaran S, Passadakis P, Bargman J, Var S, Oreopoulos D. Decline in S. aureus exit site infection and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-70.
103. Casey M, Taylor J, Clinard P, Graham A, Mauck V, Spainhour L, et al. Application of mupirocin cream at the exit-site reduces exit-infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20: 566-74.
104. Uttley L, Smart B, Hutchinson A, Gokal R. Decrease in infections with the introduction of mupirocin dream at the catheter exit-site Perit Dial Int 2001; 21 (suppl 2): S86.
105. Boer WH. Daily nasal and exit-site mupirocin application greatly reduces the S. aureus peritonitis rates without causing mupirocin resistance. (Abstract). Perit Dial Int 2001; 21 (suppl 2): S122.
106. Ramos RL, Teixeira LA, Ormonde LR, Siqueira PL, Santos MS, Marangoni D, et al. Emergence of mupirocin resistance in multiresistant Staphylococcus aureus clinical isolates belonging to Brazilian epidemic clone III: B:A. J Med Microbiol 1999; 48: 303-7.
107. Netto Dos Santos KR, De Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant S. aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996; 17: 813-16.
108. Vasquez JE, Walker ES, Franzus MS, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veteran's Affair hospital. Infect Control Hosp Epidemiol 2000; 7: 459-64.
109. Leski TA, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski K, Hryniewicz W. Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J Clin Microbiol 1999; 37: 2781-8.
110. Nakagawa S, Imuma Y, Yamamoto H, Nakao M, Sugiura S, Nishino T. Detection of mupirocin resistant staphylococci from patients treated with mupirocin. Kansenshogaku Zasshi 2001; 75: 7-13.
111. Cookson BD. The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998; 41: 11-8.
112. Wodford N, Watson AP, Patel S, Jevon M, Waghorn DJ, Cookson BD. Heterogeneous location of the mupA high-level mupirocin resistance gene in Staphylococcus aureus. J Med Microbiol 1998; 47: 829-35.
113. Thomas DG, Wilson JM, Day MJ, Russell AD. Mupirocin resistance in staphylococci: Development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro. J Appl Microbiol 1999; 86: 715-22.
114. Gilbart J, Perry CR, Slocombe B. High-level resistance in Staphylococcus aureus: Evidence for two distinct isoleucyl-tRNA synthetases. Antimicrobial Agents Chemother 1993; 37: 32-8.
115. Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554-9.
116. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-41.
117. Baird D, Coia J. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 387-8.
118. Smith MD, Sanghrijka M, Lock S. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; 2: 1472-3.
119. Alarcon T, Sanz JC, Blanco F, Domingo D, Lopez-Brea M, High-level mupirocin resistance among Spanish methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1998; 17: 877-9.
120. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42: 489-95.
121. Riley TB, Carson CF, Bowman RA, Mulgrave L, Golledge CL, Pearman JW, et al. Mupirocin-resistant methicillin-resistant Staphylococcus aureus in Western Australia. Med J Aust 1994; 161: 397-8.
122. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-3.
123. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39: 337-41.
124. Vas SI, Conly J, Bargman JM, Oreopoulos DG. Resistance to mupirocin: No indication of it to date while using mipirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int 1999; 19: 313-14.
125. Rosales N, Perez-Fontan M, Rodriguez-Carmona A, Garcia-Falcon T. Increasing resistance to mupirocin of Staphylococcus aureus (S. Au) strains isolated from peritoneal dialysis (PD) patients and their partners: Long term study (Abstract). Perit Dial Int 2000; 21 (suppl. 2): S5128.
126. Vasquez JE, Walker ES, Franzus MS, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affair Hospital. Infect Control Hosp Epidemiol 2000; 21: 459-64.
127. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42: 489-95.
128. Dos Santos KRN, De Souza Fonseca L, Filho PPG. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996; 17: 813-6.
129. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-3.
130. Matanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Furumoto A, et al. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect 2001; 47: 294-300.
131. Luzar MA. Exit-site infection in CAPD: A review. Contrib Nephrol 1990; 85: 57-66.
132. Pollock CA, Ibels LS, Caterson RJ, Mahony JF, Waugh DA. Continuous ambulatory peritoneal dialysis: Eight years of experience at a single center. Medicine 1989; 68: 293-308.
133. Weems JJ. Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756-66.
134. McGinley KJ, Larson EL, Leyden JJ. Composition and density of microflora in the subungual space of the hand. J Clin Microbiol 1988; 26: 950-3.
135. Prowant BF, Schmidt LM, Twardowski ZJ, et al. Peritoneal dialysis catheter exit-site care. Am Nephrol Nurs Assoc J 1988; 15: 219-23.
136. Keane W, et al. for the Advisory Committee on Peritoneal Dialysis Management of the IS PD. Adult peritoneal dialysis related peritonitis treatment recommendations. Update 2000; Perit Dial Int 2000; 20: 442-60.
137. Rao SP, Oreopoulos DG. Unusual complications of a polyurethane PD catheter. Perit Dial Int 1997; 17: 410-2.
138. Suh H, Wadhwa NK, Cabralda T, Bonanno J, Wasiluk A, Sorrento J. Persistent exit-site/tunnel infection and subcutaneous cuff removal in PD patients. In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications 1997; 13: 233-6.
139. Khanna R, Twardowski ZJ. Recommendations for treatment of exit-site pathology. Perit Dial Int 1996; 16: (Suppl 3): S100-4.
140. Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. Perit Dial Int 1998; 18: 11-33.
141. Lehey DJ, Gandhi VC, Daugirdas JT. Peritonitis and exit-site infection. In: Daugirdas JT, Ing TS, eds. Handbook of Dialysis. 2nd ed. Little, Brown and Company, 1994; 338-62.
142. Kazmi HR, Raffone FD, Kliger AS, Finkelstein FO. Pseudomonas exit-site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1992; 2: 1498-501.
143. Szabo T, Siccion Z, Izatt S, Vas S, Bargman J, Oreopoulos DG. Outcome of pseudomonas aeruginosa exit-site and tunnel infections: A single center's experience. Adv Perit Dial 1999: 15: 209-12.
144. Scalamogna D, De Vecchi A, Maccano M, et al. Cuff-shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy. Nephrol Dial Transplant 1995; 10: 2325-7.
145. Piraino B, Bernardini J, Peitzman A, Sorkin M. Failure of peritoneal catheter cuff shaving to eradicate infection. Perit Dial Bull 1987; 7: 179-82.
146. Lo CV, Chu WL, Man KM, Ving S, Lee WL, Chu MF, Cheng SW, Lo WK. Pseudomonas exit-site infections in CAPD patients: Evolution and outcome of treatment. Perit Dial Int 1998: 18: 637-9.
147. Lassus A, Forstrom S, Salo O. A double-blind comparison of sulconazole nitrite 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol 1983; 108: 195-8.
148. Hsu WD, Lin SL, Wu FL, Chiang CK, Wu KD. Topical antifungal treatment cures exit-site fungal infection (case report). Am J Kidney Dis 2002: 40: E15.